I decided to do a little reverse engineering on In
Post# of 154090
(Total Views: 773)
Posted On: 07/06/2021 1:23:03 AM
I decided to do a little reverse engineering on IncellDX's financials but it seems to be to large to be true. Let's see if anyone can spot an error in my methodology.
Opko owns 29% of IncellDX. I went to their most recent 10k dated 2/18/21. Under the equity investment financials it lists the companys they are invested in, all public except IncellDX. It lists percentage owned of each company and total loss for the year. The loss is $75.4 million. I looked at each company's loss multiplied by the percentage owned. For example - Pharmsynthez -527,211,000 loss x .09 percent owned = approx. $47.4 million of the $75.4 million was due to them. Adding losses and percentages of each company except IncellDX = $48.8 million.
By those figures $75.4 million - $48.8 million would leave a net loss for Opko's 29% share of IncellDX at $26.6 million. With that being the case total net loss for IncellDx would be $91.5 million.
That seems absurdly large for IncellDx. There must be a flaw in my methodology but I can't spot it.
https://www.opko.com/investors/sec-filings/annual-reports#
Opko owns 29% of IncellDX. I went to their most recent 10k dated 2/18/21. Under the equity investment financials it lists the companys they are invested in, all public except IncellDX. It lists percentage owned of each company and total loss for the year. The loss is $75.4 million. I looked at each company's loss multiplied by the percentage owned. For example - Pharmsynthez -527,211,000 loss x .09 percent owned = approx. $47.4 million of the $75.4 million was due to them. Adding losses and percentages of each company except IncellDX = $48.8 million.
By those figures $75.4 million - $48.8 million would leave a net loss for Opko's 29% share of IncellDX at $26.6 million. With that being the case total net loss for IncellDx would be $91.5 million.
That seems absurdly large for IncellDx. There must be a flaw in my methodology but I can't spot it.
https://www.opko.com/investors/sec-filings/annual-reports#
(3)
(0)